Novel peptide inhibitors of the potassium voltage-gated channel Kv1.3 as therapeutics for autoimmune diseases

Project: Research

Project Description

Two lead series of potent and selective peptide inhibitors of the potassium voltage-gated channel Kv1.3, with potential application for the treatment of a range of autoimmune (AI) diseases. Kv1.3 is a driver of AI disease, and selectively blocking Kv1.3 is gaining recognition as a new immunotherapeutic approach for AI diseases.
StatusActive
Effective start/end date23/10/1823/10/19